Cue Biopharma Narrows Q2 Loss Amidst Zero Revenue

Ticker: CUE · Form: 10-Q · Filed: Aug 12, 2025 · CIK: 1645460

Sentiment: bearish

Topics: Biotechnology, Immunotherapy, Clinical Stage, Net Loss, R&D Expenses, Pre-revenue, Capital Raise

TL;DR

**CUE is burning cash with no revenue, making it a high-risk bet on future drug success.**

AI Summary

Cue Biopharma, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with the prior year periods, indicating its pre-commercial stage. The net loss for the three months ended June 30, 2025, was $20.5 million, a decrease from $22.1 million in the same period of 2024. For the six months ended June 30, 2025, the net loss was $41.2 million, compared to $44.5 million in 2024. Research and development expenses decreased to $16.5 million for the three months ended June 30, 2025, from $18.1 million in 2024, and to $33.2 million for the six months ended June 30, 2025, from $36.5 million in 2024. General and administrative expenses remained relatively stable at $4.0 million for the three months and $8.0 million for the six months ended June 30, 2025, compared to $4.0 million and $8.0 million in 2024, respectively. The company issued 2025 pre-funded warrants on April 14, 2025, and continues to manage its cash burn while advancing its pipeline. Strategic outlook remains focused on clinical development, with no significant new collaborations or major business changes reported in this period.

Why It Matters

Cue Biopharma's continued lack of revenue and reliance on capital raises, such as the 2025 pre-funded warrants issued on April 14, 2025, signals high risk for investors, as its valuation is entirely dependent on future clinical success. The slight reduction in net loss and R&D expenses suggests some cost management, but without a clear path to commercialization, the company remains in a precarious position. For employees, job security is tied to successful drug development and continued funding. Customers (future patients) are awaiting potential therapeutic breakthroughs, while the broader market watches for innovation in the competitive immunotherapy space, where companies like Merck and Bristol Myers Squibb dominate.

Risk Assessment

Risk Level: high — Cue Biopharma reported no revenue for the three and six months ended June 30, 2025, and a net loss of $41.2 million for the six months ended June 30, 2025. This pre-revenue status, coupled with ongoing significant R&D expenses of $33.2 million for the six-month period, indicates a high reliance on external financing and a long path to profitability, posing substantial risk to investors.

Analyst Insight

Investors should approach CUE with extreme caution, recognizing it as a highly speculative investment. Monitor clinical trial progress closely and assess the company's cash runway, as continued dilution through capital raises like the 2025 pre-funded warrants is likely without a revenue stream.

Financial Highlights

debt To Equity
N/A
revenue
$0
operating Margin
N/A
total Assets
N/A
total Debt
N/A
net Income
-$20.5M
eps
N/A
gross Margin
N/A
cash Position
N/A
revenue Growth
0.0%

Revenue Breakdown

SegmentRevenueGrowth
Product Sales$00.0%

Key Numbers

Key Players & Entities

FAQ

What was Cue Biopharma's revenue for the second quarter of 2025?

Cue Biopharma, Inc. reported no revenue for the three months ended June 30, 2025, consistent with the prior year period, as the company remains in a pre-commercial stage.

How did Cue Biopharma's net loss change in Q2 2025 compared to Q2 2024?

Cue Biopharma's net loss for the three months ended June 30, 2025, was $20.5 million, which is a decrease from the $22.1 million net loss reported for the same period in 2024.

What were Cue Biopharma's research and development expenses for the first half of 2025?

For the six months ended June 30, 2025, Cue Biopharma's research and development expenses were $33.2 million, a decrease from $36.5 million in the corresponding period of 2024.

When did Cue Biopharma issue its 2025 pre-funded warrants?

Cue Biopharma issued its 2025 pre-funded warrants on April 14, 2025, as part of its financing activities.

What is the significance of Cue Biopharma having no revenue?

The absence of revenue signifies that Cue Biopharma is a clinical-stage biotechnology company, meaning its products are still in development and have not yet reached commercialization, making it reliant on external funding.

How stable were Cue Biopharma's general and administrative expenses in Q2 2025?

Cue Biopharma's general and administrative expenses remained stable at $4.0 million for the three months ended June 30, 2025, matching the $4.0 million reported in the same period of 2024.

What is Cue Biopharma's primary business focus based on its financial statements?

Based on its financial statements showing significant R&D expenses and no revenue, Cue Biopharma's primary business focus is on the research and development of its therapeutic pipeline, particularly in immunotherapy.

What are the main risks for investors in Cue Biopharma?

The main risks for investors in Cue Biopharma include its pre-revenue status, significant ongoing net losses of $41.2 million for the first half of 2025, and the inherent uncertainties and high costs associated with clinical drug development.

Does Cue Biopharma have any active collaboration agreements mentioned in the filing?

Yes, the filing mentions collaboration agreements such as the 'Ono Collaboration and Option Agreement' and the 'LG Chem Life Sciences Collaboration Agreement', indicating ongoing partnerships.

What is the company's fiscal year end?

Cue Biopharma's fiscal year end is December 31, as stated in the filing data.

Risk Factors

Industry Context

The pharmaceutical preparations industry is characterized by high R&D investment, long development cycles, and significant regulatory hurdles. Companies like Cue Biopharma operate in a competitive landscape where innovation is key, but success is often dependent on clinical trial outcomes and eventual market approval. The industry is also subject to evolving healthcare policies and reimbursement landscapes.

Regulatory Implications

As a biopharmaceutical company, Cue Biopharma is subject to stringent regulations from bodies like the FDA. Successful navigation of clinical trials and obtaining regulatory approval are critical milestones. Any delays, setbacks, or adverse findings in these processes can significantly impact the company's development timeline and financial viability.

What Investors Should Do

  1. Monitor R&D progress and clinical trial updates.
  2. Assess cash burn rate and future financing needs.
  3. Evaluate the competitive landscape and market potential for pipeline candidates.

Key Dates

Glossary

Pre-commercial stage
A phase in a company's lifecycle where it has not yet begun generating revenue from product sales, typically focusing on research, development, and clinical trials. (Explains why Cue Biopharma has zero revenue and is focused on R&D expenses.)
Net Loss
The total expenses incurred by a company exceed its total revenues over a specific period. (Indicates the company's profitability, showing a loss of $20.5 million for Q2 2025.)
Research and Development (R&D) Expenses
Costs incurred by a company in the process of developing new products or services, or improving existing ones. (Represents the primary expenditure for Cue Biopharma, totaling $16.5 million for Q2 2025, reflecting its focus on pipeline advancement.)
General and Administrative (G&A) Expenses
Costs associated with the overall management and operation of a business, not directly tied to a specific product or service. (Shows the overhead costs of the company, which remained stable at $4.0 million for Q2 2025.)
Pre-funded Warrants
A type of warrant that allows the holder to purchase shares of common stock at a nominal exercise price, often used in financing rounds to provide immediate capital. (The issuance on April 14, 2025, signifies a recent capital infusion for the company.)

Year-Over-Year Comparison

Compared to the prior year's comparable periods, Cue Biopharma reported zero revenue for both the three and six months ended June 30, 2025, indicating its continued pre-commercial status. Net losses have slightly decreased, with Q2 2025 at $20.5 million versus $22.1 million in Q2 2024, and the six-month loss at $41.2 million versus $44.5 million in 2024. Research and development expenses also saw a reduction, falling to $16.5 million for Q2 2025 from $18.1 million in 2024, and $33.2 million for the six months from $36.5 million. General and administrative expenses remained stable year-over-year.

Filing Stats: 4,442 words · 18 min read · ~15 pages · Grade level 16.5 · Accepted 2025-08-12 16:00:53

Key Financial Figures

Filing Documents

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Financial Statements (Unaudited)

Item 1. Financial Statements (Unaudited) 6 Condensed Consolidated Balance Sheets 6 Condensed Consolidated Statements of Operations and Comprehensive Loss 7 Condensed Consolidated Statements of Stockholders' Equity 8 Condensed Consolidated Statements of Cash Flows 9 Notes to the Condensed Consolidated Financial Statements (Unaudited) 10

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 28

Quantitative and Qualitative Disclosures about Market Risk

Item 3. Quantitative and Qualitative Disclosures about Market Risk 41

Controls and Procedures

Item 4. Controls and Procedures 41

OTHER INFORMATION

PART II. OTHER INFORMATION

Legal Proceedings

Item 1. Legal Proceedings 42

Risk Factors

Item 1A. Risk Factors 42

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 44

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 44

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 44

Other Information

Item 5. Other Information 44

Exhibits

Item 6. Exhibits 45 2 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY DATA This Quarterly Report on Form 10-Q contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "would," "could," "seek," "intend," "plan," "goal," "project," "estimate," "anticipate," "strategy," "future," "likely" or other comparable terms. All statements, other than statements of historical fact, contained in this Quarterly Report on Form 10-Q, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans and objectives of management, are forward-looking statements. The forward-looking statements in this Quarterly Report on Form 10-Q include, among other things, statements about: the initiation, timing, progress and results of our ongoing and planned preclinical studies and any future clinical trials and our research and development programs; our estimates regarding expenses, future revenue, capital requirements and need for additional financing; our expectations regarding our ability to fund our projected operating requirements with our existing cash resources and the period in which we expect that such cash resources will enable us to fund such operating requirements; our plans to develop our drug product candidates, including our prioritization of our autoimmune programs, including CUE-401 and the CUE-500 series (excluding CUE-501, which has been licensed to Boehringer Ingelheim International GmbH); our plans to pursue third party support through partnerships and collaborations to further develop the CUE-100 ser

Financial Sta tements

Item 1. Financial Sta tements Cue Biopharma, Inc. Condensed Consolidated Bal ance Sheets (Unaudited) (in thousands, except share and per share amounts) June 30, 2025 December 31, 2024 ASSETS Current assets: Cash and cash equivalents $ 27,492 $ 22,459 Accounts receivable 532 945 Deposits, current portion 470 929 Prepaid expenses and other current assets 2,350 805 Total current assets 30,844 25,138 Property and equipment, net 454 471 Operating lease right-of-use asset 5,118 4,370 Deposits 1,956 1,955 Restricted cash 153 152 Other long-term assets 283 105 Foreign withholding tax receivable 1,899 — Total assets $ 40,707 $ 32,191 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 3,627 $ 2,823 Accrued expenses 1,518 2,908 Research and development contract liability, current portion 9,579 85 Operating lease liabilities, current 2,114 3,540 Current portion of long-term debt, net 2,416 4,333 Total current liabilities 19,254 13,689 Operating lease liabilities, non-current 3,104 1,003 Other long-term payable 190 — Total liabilities $ 22,548 $ 14,692 Commitments and contingencies (Note 11) Stockholders' equity: Preferred stock, $ 0.001 par value; 10,000,000 shares authorized and 0 shares issued and outstanding at June 30, 2025 and December 31, 2024 — — Common stock, $ 0.001 par value; 300,000,000 shares authorized; 76,446,884 and 61,819,101 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively 76 62 Additional paid in capital 380,686 359,301 Accumulated deficit ( 362,603 ) ( 341,864 ) Total stockholders' equity 18,159 17,499 Total liabilities and stockholders' equity $ 40,707 $ 32,191 The accompanying notes are an integral part of these condensed consolidated financial statements. 6 Cue Biopharma, Inc. Conden

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing